South Korea enacts pharmaceutical law to protect patents involving new drug applications and supplements
-
Last Update: 2020-07-06
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On October 16, 2007, Korea enacted a pharmaceutical law to comply with the Free Trade Agreement (FTA) between Korea and the United States and to protect patents relating to the application and supplementation of new drugsThe contents include: patent information ondrugapproved in the list of registered patents, and disclosure to the public, a notice of application to confirm the application containing data on the safety and efficacy of the product signed in the patent list, patent litigation within 30 days of receipt of the above notice, and trial approval of the patent owner in cases of patent infringement or patent invalidity
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
![benzyl N-{2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl}carbamate](https://file.echemi.com/fileManage/upload/goodpicture/20210823/m20210823171124543.jpg)
